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ABSTRACT
Hematopoietic stem cells (HSC) are maintained in a tightly regulated bone microenvironment constituted by a rich milieu of cells. Bone cells
such as osteoblasts are associated with niche maintenance as regulators of the endosteal microenvironment. Bone remodeling also plays a role
in HSC mobilization although it is poorly defined. The effects of zoledronic acid (ZA), a potent bisphosphonate that inhibits bone resorption,
were investigated on bone marrow cell populations focusing on HSCs, and the endosteal and vascular niches in bone. ZA treatment
significantly increased bone volume and HSCs in both young and adult mice (4 week and 4 month old, respectively). ZA increased vessel
numbers with no overall change in vascular volume in bones of young and had no effect on vasculature in adult mice. Since both young and
adult mice had increased HSCs and bone mass with differing vasculature responses, this suggests that ZA indirectly supports HSCs via the
osteoblastic niche and not the vascular niche. Additionally, gene expression in Lin- cells demonstrated increased expression of self-renewal-
related genes Bmi1 and Ink4a suggesting a role of ZA in the modulation of cell commitment and differentiation toward a long-term self-
renewing cell. Genes that support the osteoblastic niche, BMP2 and BMP6were also augmented in ZA treatedmice. In conclusion, ZA-induced
HSC expansion occurs independent of the vascular niche via indirect modulation of the osteoblastic niche. J. Cell. Biochem. 114: 67–78,
2013.  2012 Wiley Periodicals, Inc.
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B one is an important hematopoietic organ tightly regulated bythe diverse cellular components that constitute its microen-
vironment. This unique microenvironment, also known as the stem
cell niche, maintains and regulates hematopoietic stem cells (HSCs).
HSCs are found in close association with the endosteal interface of
bone and bone marrow, and perivascular sinusoidal blood vessels
[Kiel et al., 2005; Adams et al., 2006]. Osteoblasts, endothelial cells,
adipocytes and stromal cells are key cells that constitute the
niche and participate in the regulation and maintenance of HSCs
[Bianco, 2011]. The hematopoietic niche is necessary to balance the
expansion and mobilization of HSCs to the peripheral blood as
well as the regulation of self-renewal capacity and hematopoietic
commitment to differentiation. Moreover, the bone microenviron-
ment plays an important role in this regulation. For instance, studies
have demonstrated that increased osteoblast number augments HSC
numbers in bone marrow [Calvi et al., 2003; Zhang et al., 2003]
whereas, osteoblast depletion leads to a reduction in HSC numbers
[Visnjic et al., 2004]. It is not well defined whether enrichment of
bone structures such as vasculature or the endosteum can alter the
HSC pool in bone marrow. In this context, therapies that involve
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modulation of bone formation or remodeling may affect HSC
expansion and mobilization.
Osteoclasts are believed to play a role in the bone microenviron-
ment and consequently affect the HSC microenvironment. For
instance, osteoclast-induced bone resorption is responsible for the
release of various growth factors, proteins, and bone mineral such as
calcium, all of which are known to influence in the hematopoietic
cells and niche maintenance and mobilization [Adams et al., 2006;
Kollet et al., 2006]. Still, the precise role of osteoclasts in HSC niche
maintenance and mobilization is ill defined and controversial.
Although augmented osteoclast activation results in increased
stress-induced mobilization of HSCs [Cho et al., 2010], osteopetrotic
animal models and pharmacological strategies of osteoclast
inhibition resulted in increased mobilization of HSCs in response
to G-CSF stimulation [Miyamoto et al., 2011].
Pharmacologic strategies such as bisphosphonates inhibit
osteoclast-mediated bone resorption. Zoledronic acid (ZA) is a
potent third generation bisphosphonate utilized for treatment of
metabolic bone diseases such as osteoporosis, Paget’s disease and
cancer-related bone diseases. The high affinity for hydroxyapatite
results in accumulation in bone that when it is resorbed by
osteoclasts inhibition of the mevalonate pathway and apoptotic cell
death occurs [Rodan and Fleisch, 1996; Winter and Coleman, 2009].
However, the mechanisms of which osteoclast inhibition affects the
HSC niche and progenitor cells expansion are yet unclear.
It was hypothesized that osteoclasts may play an important role in
hematopoiesis in the bone marrow. In this study, mice were treated
with ZA, and HSCs in bone analyzed. Altogether, the treatment
differential response in the different hematopoietic progenitor and
stem cells suggests that osteoclast inhibition and changes in the
bone microstructure may play a role in the increased hematopoietic
stem cells in the bone marrow.
MATERIALS AND METHODS
TREATMENT WITH ZOLEDRONIC ACID (ZA)
All animals were maintained in accordance with institutional
animal care and use guidelines and experimental protocols
approved by the Institutional Animal Care and Use Committee of
the University of Michigan. Male C57BL/6J mice at 4- or 16-weeks
of age were obtained from the Jackson Laboratory (Bar Harbor, ME).
Intraperitoneal injections were performed twice/week with 200mg/kg
of ZA (Zometa, Novartis, Stein, Switzerland) or vehicle (saline) for
up to 4 weeks. At sacrifice, blood and hind limbs were collected for
analyses.
FLOW CYTOMETRY ANALYSIS (FACS)
One femur and one tibia were collected and flushed with FACS
buffer (PBS, 1%FBS, 2 nM EDTA). The enriched central bone marrow
cells were filtered through a 100mm cell strainer and cells were
enumerated and resuspended to a total of 5million cells/500mL. Lin
cocktail (APC), Sca-1 (E13-161.7, PE), c-kit (2B8, FITC) antibodies
were used to quantify the Lin-Sca1þc-Kitþ cells. To evaluate the
SLAM population (CD48 CD41 CD150þ Sca1þ c-kitþ) cells were
incubated with the antibodies Sca-1 (E13-161.7, biotin), c-kit (2B8,
APC), CD48 (HM48-1, FITC), and CD41 (MWReg30, FITC),
CD150(TC15-12F12.2, PE-Biolegend). For the long-term reconsti-
tution assay analysis, peripheral blood cells were stained with CD3,
CD5, B220 (Ra3-6B2, PE). Endothelial progenitor cells (EPC) were
identified as CD11b (M1/70, APC) CD34þ (RAM34, FITC-
eBioscience) and Flt1þ(Avas12a1, PE-eBioscience) cells. After
antibody incubation cells were washed twice with PBS and
evaluated with a FACsCalibur (BD Bioscience, San Jose, CA). All
other antibodies used for flow cytometry were purchased from BD
Bioscience.
LONG-TERM COMPETITIVE RECONSTITUTION ASSAYS
For in vivo enumeration of HSCs, 300,000 CD45.2 bonemarrow cells
were isolated from ZA-treated and untreated C57BL/6mice and were
mixed with 300,000 CD45.1 cells from CD45.1 congenic mice. Cells
were then intravenously injected into CD 45.2/CD45.1 recipient mice
that had been lethally irradiated with 850 cGy of irradiation. Four
weeks after transplantation, the frequency of the different cell
populations were determined in the peripheral blood (PB) by
fluorescence-activated cell sorting (FACS) using PE-CD45.1 and
FITC-CD45.2 antibodies (BD Pharmingen) over a 3 month period.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
After 4 weeks of treatment, mice were sacrificed and tibiae were
collected and fixed in 10% formalin. Decalcification was performed
in 10% EDTA for 14 days prior to paraffin embedding. Paraffin-
embedded specimens were sectioned at 5mm and stained with
hematoxylin and eosin (H&E), or tartrate-resistant acid phosphatase
(TRAP) to detect osteoclasts (Acid Phosphatase, Leukocyte Kit,
Sigma, St. Louis, MO) or with Von Willebrand factor (vWF) to
identify vascular spaces. For microvessel density (MVD) analysis,
after vWF staining, four random areas were selected. Any single or
cluster of positively stained endothelial cells that was clearly
separated from adjacent microvessels was considered as one
countable microvessel. The average MVD was determined for
each specimen. Mayer’s hematoxylin (Sigma) was used for
counterstaining.
RNA ISOLATION AND QUANTITATIVE PCR ASSAY
One tibia and femur were flushed with PBS and cells were sorted into
Lin, Linþ using magnetic cell sorting microbeads (MACS). After
sorting, cells were pelleted and RNA was isolated with Tri reagent
(Sigma) following the manufacturer’s protocols. One microgram of
total RNA was reverse transcribed in a 20-mL reaction volume
containing random hexamers using a reverse-transcription assay
system (Applied Biosystems, Foster City, CA). Quantitative reverse
transcription-PCR (RT-PCR) was performed using the ABI PRISM
7700 with a ready-to-use mix of primers and FAM-labeled probe
assay system (Applied Biosystems). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a reference and the delta delta
CT method were used to calculate the data.
SERUM TRAP5b AND CALCIUM MEASUREMENT
Serum TRAP5b activity was measured by ELISA (Immunodiagnostic
Systems, Inc.) following the manufacturer’s instructions. A
quantitative colorimetric assay with Calcium Reagent Set (Pointe
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Scientific, Inc., Canton, MI) was used to measure the total calcium
levels in serum and bone marrow supernatants.
MIROFIL AND MICRO CT ANALYSES
A perfusion technique using the radiopaque silicone rubber
injection agent Microfil TM followed by microCT analysis was
utilized as previously described [Guldberg et al., 2008; Park et al.,
2012]. Briefly, mice treated with vehicle or zoledronic acid for
4 weeks were anesthetized and perfused with lactated Ringer’s
solution containing heparin, followed by 10% neutral buffered
formalin, and then with a MicrofilTM compound of 1.04 specific
gravity mixed 4:1 with a 0.92 specific gravity diluent. Femora,
tibiae, and spleens were dissected, and bones were fixed and
decalcified. Samples were scanned in air at a 7 um voxel size by
microcomputed tomography (eXplore Locus SP (GE Healthcare Pre-
Clinical Imaging, London, ON, Canada). Regions of interest were
defined for both central bone vascularity and vascular regions near
the growth plate, and quantitative differences in vessel numbers and
sizes were determined using the stereology package of commercially
available software (MicroView v2.2, GE Healthcare Pre-Clinical
Imaging, London, ON, Canada).
STATISTICAL ANALYSIS
The GraphPad Instat 3 software program (GraphPad Software, San
Diego, CA) was used to analyze the differences by one-way ANOVA
or Student’s t-test for independent analysis. The value P< 0.05 was
considered statistically significant. All assays were repeated at least
twice with similar results.
RESULTS
ZA TREATMENT INCREASED BONE AREA AND OSTEOCLAST
ACTIVITY IN YOUNG MICE
To elucidate the role of osteoclasts in the bonemicroenvironment, 4-
week-old mice were treated with vehicle (saline) or zoledronic acid
(ZA) twice a week for 4 weeks. As expected, ZA treated mice had
increased bone volume, increased trabecular thickness and number,
and decreased trabecular spacing (Fig. 1 A–D). Serum tartrate-
resistant acid phosphatase 5b (TRACP 5b) serum levels were
decreased (Fig. 1E) as well as osteoclast numbers in marrow
following ZA treatment (Fig. 1F). ZA treatment decreased the
calcium levels in the bone marrow (Fig. 1G) but did not alter serum
calcium levels (Fig. 1H) as previously reported [Li et al., 2011].
Altogether, the inhibition of osteoclasts by ZA resulted in increased
bone mass.
HEMATOPOIETIC PROGENITOR CELLS WERE INCREASED AFTER
ZA TREATMENT
To investigate the effects of osteoclast inhibition on hematopoiesis,
mice were treated with ZA or vehicle for 4 weeks and the bone
marrow cells were analyzed by FACS at different time points.
Hematopoietic progenitor cells (LinSca-1þc-kitþreferred to as LSK)
were significantly increased when compared to the vehicle treated
mice (Fig. 2A). Since hematopoietic progenitor cells were increased
the long-term reconstitution hematopoietic stem cells were also
analyzed using the SLAM markers (CD48CD41CD150þSca1þ
c-Kitþ) as previously described [Kiel et al., 2005]. As was observed
with the number of LSK cells following ZA treatment, a trend of
increased SLAM cells was observed with ZA treatment although it
did not reach statistical significance (P¼ 0.056; Fig. 2B).
LONG-TERM RECONSTITUTION OF LYMPHOID CELLS WAS HIGHER
IN ZA TREATED MICE
Since hematopoietic cells bearing the LSK and SLAM phenotype
were increased in mice treated with ZA, their capacity for long term
reconstitution was analyzed. Bone marrow cells were collected
from isogenic CD45.1 mice treated with ZA or vehicle and mixed
with CD45.2 donor cells at equal cell numbers (Fig. 3A). Cells were
transplanted into recipient mice (CD45.2) that had received lethal
irradiation and engraftment of the CD45.1 donor cells was
monitored in blood over a 3 month period. Lymphoid cells were
increased in mice treated with ZA with higher B and T lymphocytes
(Fig. 3B,C). There were no differences in the myeloid cell populations
(Fig. 3D).
Collectively the data show that HSCs are increased in the marrow
following ZA treatment. To explore the mechanisms which could
account for these data, three potential pathways which could lead
to increased HSCs were explored: (1) ZA reduced hematopoietic
stem cell egress or mobilization from the marrow and subsequent
retention of the cells in the bone marrow, (2) ZA increased endosteal
or vascular niches allowing for greater localization of HPCs/HSCs, or
(3) ZA altered stem cell composition and differentiation.
HEMATOPOIETIC STEM CELL MOBILIZATION
To determine the extent to which ZA alters HSC egress or
mobilization from the marrow, peripheral blood and spleens were
analyzed by FACS in mice treated with ZA or vehicle. As a result of
the ZA treatment, LSK numbers in the peripheral blood were not
altered (Fig. 4A). No correlation was seen between LSK numbers in
bone marrow and peripheral blood (data not shown). To investigate
whether ZA has an effect on HSC mobilization or extramedullary
hematopoiesis, the spleens of vehicle or ZA treated animals were
analyzed. Spleen weight/body weight and LSK numbers in mice with
ZA or vehicle were not significantly different (Fig. 4B,C). Altogether,
these data suggest that increased LSKs in the bone marrow were not
due to mobilization effects in mice treated with ZA.
ENDOSTEAL AND VASCULAR NICHES
The hematopoietic niche is formed in the bone marrow by
hematopoietic and non-hematopoietic cells and localized in the
endosteum (area between bone marrow and bone) and sinusoids.
ZA increases bone mass and thus provides an increase in niches
to support HSCs. Interestingly, we observed in the bone sections of
mice that augmented trabecular bone was also followed by increased
small vessels number in 4 week old mice (Fig. 5A). Therefore,
changes in the vasculature of bone in mice treated with ZA or
vehicle for 4 weeks were examined. Radiopaque silicone rubber
agent MicrofilTM was perfused intravenously and micro CT analysis
of vascular spaces was performed (Fig. 5B–F). Although the overall
vessel volume fraction was not affected (Fig. 5C), ZA treated mice
had reduced vessel thickness (Fig. 5D) and increased vessel numbers
(Fig. 5E). In addition, bone sections were stained for VonWillebrand
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factor (vWF) and vessel numbers were quantified (Fig. 5G).
Consistent with the Micro CT analyses, vessel number was increased
with ZA treatment.
HEMATOPOIETIC CELL COMPOSITION
The changes seen in the hematopoietic progenitor cell populations
could also be due to changes in the hematopoietic composition of
the bone marrow. To assess whether ZA affected the mature
hematopoietic composition, bone marrow was analyzed for CD41þ
cells by FACS and no significant changes were observed (Fig. 6A). In
addition, peripheral blood cell count was performed and there was
no alteration in the white and red blood cells or platelets (Fig. 6B).
The other possibility could be that zoledronic acid induced
changes in the bone could be affecting the hematopoietic stem cell
differentiation into progenitor cells. Thus, we decided to further
investigate the constitution of the HSC population. Stem cells are
classified according to their repopulation capacity into long-term
HSCs (LT-HSC) and short-term HSCs (ST-HSCs). The LT-HSCs are
Fig. 1. ZA treatment effects on bone area and osteoclast activity. Four-week-old C57BL/6J male mice were treated with 200mg/kg of ZA twice/week for 4 weeks. A–D: ZA
treatment increased bone area. (A–D) Histomorphometric analysis of tibiae shows an increase of bone volume (BV/TV %), trabecular thickness (Tb Th, mm) and
number(Tb number mm1), and decreased trabecular spacing (Tb Sp,) in tibiae from ZA treated mice versus vehicle (VEH); E: blood serum TRAP5b levels were reduced
with ZA treatment; F: representative TRAP staining of tibia; G–H: bone marrow calcium levels were decreased and serum calcium levels were not changed; Calcium levels were
measured in the bone marrow (G) and serum (H) of mice treated with ZA or vehicle for up to 4 weeks; (T/C) Treatment/control (P< 0.05; P< 0.01; P< 0.005 versus vehicle
[VEH]). Data are presented as mean SEM, n¼ 8/gp (A–E, G–H).
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stem cells that present extensive life long, self-renewing potential
and are capable of repopulating the whole hematopoietic system. In
contrast, ST-HSCs have a lower self-renewing capacity but a rapid
capability of myeloerythroid cell repopulation [Yang et al., 2005].
They can be identified according to the expression of cytokine
polypeptide deformylase (fms)—like tyrosine kinase receptor 3
(Flt3): long-term-HSCs are LSK CD34Flt3 and short-term-HSCs
(LSK CD34þ) can be further divided into two subsets. ST-HSCs Flt3þ
for cells with great lymphoid reconstitution and ST-HSCs Flt3 for
rapid myelopoiesis. Because increased LSK numbers were observed,
Fig. 2. ZA treatment increased LSK population but not long-term hematopoietic stem cells. Mice were treated with 200mg/kg of ZA twice/week for 4 weeks and bone marrow
cells were analyzed by flow cytometry. A: ZA treatment increased bone marrow LinSca1þ c-Kitþ hematopoietic progenitor cells after 4 weeks of treatment versus vehicle (VEH)
control. B: ZA treatment did not affect the long-term hematopoietic stem populations as identified using SLAM markers (CD48CD41CD150þSca1þc-Kitþ; P< 0.005) T/
C¼ treatment/control. Data are presented as mean SEM, n¼ 5/gp.
Fig. 3. Long-term HSC reconstitution was increased in ZA treated bone marrow cells. Donor CD45.1 mice were treated for 4 weeks with ZA or vehicle (VEH). Bone marrow cells
were collected and mixed with rescue donor CD45.2 bone marrow cells. Mixed cells were injected intravenously in irradiated recipient mice, and blood cells were collected and
analyzed by flow cytometry as indicated for CD45.1 positive and (A) B cells (B220), (B) T-cells (CD3), and (C) myeloid cells (Gr-1). Zoledronic acid treated mice had increased
reconstitution of the B and T cell populations but no altered reconstitution of the myeloid Gr-1 population (P< 0.01, P< 0.05). Data are presented as mean SEM, n¼ 10.
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we investigated the differentiation stage of the LSK population.
Indeed LSK Flt3þ (ST-HSCs) were increased with ZA treatment
(Fig. 6C) suggesting that cells with great lymphoid reconstitution are
augmented by ZA induced changes in the bone microenvironment,
as seen in the long term reconstitution assay (Fig. 3B,C).
To investigate whether ZA influenced bone angiogenesis, we
also measured endothelial progenitor cells (EPCs) by FACS in both
bone and peripheral blood (Fig. 6D,E). ZA treatment significantly
decreased CD11b CD34þ Flt1þ EPCS at 3 weeks only but at 4 weeks
no difference was seen (Fig. 6D) in bone or in the peripheral blood
(Fig. 6E).
GENE EXPRESSION ANALYSES
To further confirm the HSC population commitment, bone marrow
cells were sorted into Lin or Linþ cells and gene expression of
hematopoietic related genes were analyzed. Lineage negative cells
had increased expression of BMP2, BMP6, Bmi1, Tie2, Notch1, but
no change in Ink4a, in mice treated with ZA (Fig. 7A). BMP2 and
BMP6 are proteins known to support endosteal niche maintenance,
suggesting an active participation of HSCs in the endosteal niche.
Bmi1, Ink4a, and Tie2 genes are indicators of self-renewal capacity
[Park et al., 2003]. Bmi1 is required for HSC self-renewal since
Bmi1/ mice have normal HSCs in fetal liver but decreased HSC
numbers in postnatal mice. p16Ink4a is downstream of Bmi1 and
participates in the regulation of HSC proliferation [Smith et al.,
2003].
Because ZA may affect the calcium resource in bone due to the
inhibition of bone resorption we also investigated calcium related
genes in linage negative cells and found calmodulin 1 (Cam1) and
calcium chloride channel (ClCa1) were decreased with ZA treatment
(Fig. 7B).
Linage positive cells had decreased gene expression for BMP6 but
no significant changes were observed in Bmi1, Tie2, Notch1, Ink4a,
and Flt3 (Fig. 7C). Total bone marrow cells had decreased gene
expression of osteocalcin (OCN) and vascular cell adhesion molecule
1 (VCAM1) genes (Fig. 7D). Altogether, the increased LSK population
may be in part due to increased self-renewal capacity and
suppression of linage commitment towards short-term hematopoi-
etic stem cells.
ADULT MODEL VASCULATURE AND HSCS
Because the experiments were performed in 4-week-old mice that
are in an active phase of growth and high bone activity, adult mice
were also investigated. Four-month-old mice were treated with ZA
or vehicle for 4 weeks and same analyses were performed. LSK
numbers were again increased in ZA treated mice (Fig. 8A). Micro CT
analyses of Microfil perfused mice presented no changes in vessel
volume, thickness or number, suggesting that increased LSK
numbers in 4-month-old mice were not due to increased vascular
niches (Fig. 8B–G).
DISCUSSION
In this study, treatment with ZA in both young and adult mice
significantly increased the hematopoietic progenitor population
(LSK) in the bone marrow. The augmented LSK population was
confirmed functionally by long term reconstitution assays showing
increased repopulation of B and T lymphocytes in mice that received
bone marrow stromal cells from donor mice treated with ZA. One
interesting finding was that reconstitution of Gr-1þ population
that accounts for myeloid cells was not different. A recent study
demonstrated that TGF-b1 can regulate the hematopoietic stem cell
long–term differentiation. High levels of TGF-b1 resulted in
stimulation of myeloid-biased HSCs and inhibition of lymphoid-
biased HSCs [Challen et al., 2010]. ZA is known to inhibit bone
resorption and consequently reduce the release of TGF-b1 from
resorbed bone[Wu et al., 2010]. Accordingly, with ZA treatment an
increased reconstitution of lymphocyte B and T cells were observed
but not the myeloid population suggesting that low TGF-b1 could be
modulating the reconstitution of these cells in the bone marrow.
Moreover, ZA treatment increased the LSK Flt3þ population that are
Fig. 4. Bone marrow HSC mobilization. ZA did not alter the LSK population in the blood or spleen. Four-week-old C57BL/6J male mice were treated with 200mg/kg of ZA
twice/week for 4 weeks, and peripheral blood and spleens were analyzed. A: Flow cytometry analyses of LSK population in the peripheral blood; B,C: spleen cells were
collected and LSK population was analyzed by flow cytometry (B); spleen weight/body weight were analyzed and no changes were observed (C). Data are presented as
mean SEM, n¼ 10/gp (A), n¼ 8/gp (B,C).
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known to be short term lymphocytic reconstituting cells, confirming
an effect of ZA in hematopoietic reconstitution.
Since LSK cells were increased in ZA treated mice, 3 potential
hypotheses were investigated; (1) mobilization of LSK in the bone
marrow, (2) increased bone marrow niches supporting increased
numbers of LSKs, and (3) altered cell composition and stem cell
differentiation.
Mobilization depends on detachment of HSCs from their niches
concomitantly with cellular migration and egress from bonemarrow
to the circulation. Mobilization strategies have been used clinically
to collect a large number of hematopoietic stem cells from the
blood, a less invasive procedure than bone marrow aspiration for
transplantation. Regulation of the bone microenvironment and the
niches present in the marrow are important to preserve HSCs and
therapies that interfere in this balance can affect the stem cell pool.
Based on our findings, mobilization of LSKs in ZA treated mice was
not altered since the LSK population was unchanged in the
peripheral blood as well as the spleens. No difference was seen in
Fig. 5. Effects of ZA on bone and vasculature. ZA did not alter vessel volume but increased vessel numbers in 4-week-old mice treated with ZA or vehicle (VEH) for 4 weeks.
A: H&E staining of mice treated with vehicle or ZA shows an increase of vessels in the trabecular area of mice tibiae; B–F: mice were perfused with radiopaque silicone rubber
microfil and tibiae were analyzed by micro CT; (B) Representative micro CT image of bones with microfil perfusion; C–F: MicroCT analysis of microfil for vessel volume/tissue
volume (VV/TV%), thickness (V Th, mm), numbers (VN, mm1), and spacing (VS, mm). ZA treatment decreased vessel thickness and increased vessel numbers; G: tibiae sections
were stained for Von Willebrand factor (V) and vessel numbers were quantified (P< 0.05, P< 0.01, P< 0.005). Data are presented as mean SEM, n¼ 10/gp.
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white and red blood count or in the platelet numbers in peripheral
blood. Studies demonstrated that bone remodeling is altered when
HSC mobilization is induced by granulocyte-colony stimulating
factor (G-CSF) treatment with decreased bone volume [Lee et al.,
1991; Takahashi et al., 1996]. Therefore, bone activity is closely
associated with HSC commitment for mobilization and differentia-
tion with egress of HSCs from the bone marrow. Interestingly ZA
inhibits osteoclast function and subsequently results in increased
bone volume, an opposite effect seen in G-CSF therapies.
Since ZA treatment did not stimulate the egress of LSKs from the
bone marrow to the circulation two other questions were addressed.
First was whether ZA promotion of LSK increase is due to
hematopoietic niche alteration and secondly, whether ZA regulates
the factors necessary for the retention of HSCs with modulation of
cell commitment. ZA is a bisphosphonate clinically utilized for the
treatment of bone associated diseases such as osteosporosis and
skeletal malignancies due to its inhibitory actions in osteoclast
mediated bone resorption. ZA actions in bone were confirmed by
histomorphometric analyses of bone sections demonstrating a
significant increase bone mass and decrease in osteoclast activity.
Hematopoietic niches maintain self-renewing and dormant HSCs in
the bone marrow and although still controversial, HSCs are believed
to reside in association with bone locals termed endosteal niches and
surrounding sinusoids present in the marrow, known as vascular
niches. It was also proposed that the distinct niches have different
functionalities: the endosteal niche homes and maintains long-term
HSCs and the vascular niche is involved in the short term HSC
maintenance, promoting the differentiation and circulation of HSCs
[Grassinger et al., 2010]. However, to fully differentiate both niches
is difficult due to the close association of the vasculature especially
in trabecular bone rich areas, locations where HSCs preferentially
lodge [Ellis et al., 2011]. An increase in the osteoblastic niche could
account for the augmented LSK population, especially for the long-
term LSKs that were modestly increased after ZA treatment using the
SLAM markers.
Bisphosphonates are being studied for their activities not only in
the bone microenvironment but also putative direct effects in tumor
cell proliferation, adhesion, invasion, apoptosis, and angiogenesis
[Rogers and Holen, 2011]. The anti-angiogenic effects of ZA have
been demonstrated by its actions as a potent inhibitor of endothelial
cell proliferation, adhesion migration and angiogenesis [Wood et al.,
2002; Metcalf et al., 2011]. However, ZA effects in bone vasculature
are still poorly defined. Bone vascular biology is an understudied
area and the interdependency of vascular physiology and
Fig. 6. Effects of ZA on hematopoietic cell composition. To investigate the effects of ZA on hematopoiesis and progenitor cells, bone marrow and blood cells of 4-week-old
mice were analyzed; A: no alteration in the bone marrow CD41þmature hematopoietic composition with ZA treatment versus vehicle(VEH) control; B: blood cell count of white
blood cells (WBC), red blood cells (RBC), and platelets (PLT) were not altered with ZA treatment; C: sixteen-week-old mice were treated with ZA or vehicle (VEH) for 4 weeks and
bone marrow cells were collected and LSK Flt3þ and Flt3were analyzed by flow cytometry. D–E: Endothelial progenitor cells (CD11b CD34þ Flt3þ) were analyzed over time to
investigate the effects of ZA in bone marrow and mobilization to the peripheral blood; (D) EPCs in the bone marrow were significantly decreased at 3 weeks of ZA treatment but
not significantly different at 4 weeks; (E) EPCs in the peripheral blood were not altered by ZA treatment (P< 0.05). Data are presented as mean SEM, n¼ 8/gp (T/C)
treatment/control.
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osteogenesis needs to be more thoroughly investigated. It is known
that angiogenesis and bone formation are intrinsically linked during
bone development [Wang et al., 2007] and repair [Wan et al., 2008].
Osteoclasts actively participate in this process, excavating the
marrow cavity, while sinusoids establish this unique type of bone
microcirculation [Bianco, 2011]. Although biological evidence is
observed in the bone coupling with endothelial cells [Parfitt, 2000],
the formation and modulation of the vasculature linked with bone
modeling and the effects of stimulators (hormones, drugs and
mechanical loading) that affect its microstructure are relatively
unexplored. Studies in mechanical loading, demonstrated that bone
angiogenesis was accompanied with bone gain in running rats [Yao
et al., 2004] and VEGF was the mechanism driving both effects.
Recently, an interesting study demonstrated that intermittent
parathyroid hormone (PTH) induced vascular endothelial growth
factor (VEGF A) production that mediated PTH anabolic response
[Prisby et al., 2011]. PTH treated mice had fewer blood vessel
numbers and relocated existing blood vessels near to new bone
formation sites. Interestingly, ZA treatment decreased the circulat-
ing levels of VEGF in cancer patients with bone metastasis [Santini
et al., 2003] but their effects on the bone vasculature were not
determined.
In this study, we observed the expected increase in bone mass, but
we also investigated the changes that occur in the vasculature of
mice treated with ZA. To this end, perfusion of a radiopaque microfil
was performed to visualize and quantify changes in the vasculature
volume and vessel numbers. Interestingly, young mice (4 week old)
treated with ZA had no alteration in overall vessel volume but had
increased vessel numbers that were smaller and accumulated
between the augmented trabecular areas in the metaphysis. This
finding lead us to further investigate if the changes in the bone niche
(both endosteal and vascular) microstructures contributed to the
increased LSK numbers. Because the experiments were performed in
young (4week old) mice where bone is highly active, we also
performed experiments in adult (4 month old) mice. Similar to the
young mice, LSK cells and bone mass were significantly increased
after 4 week treatment with ZA but surprisingly vessel numbers and
volumes were not changed in the adult mice. The increase in bone
vessel numbers in the young model but not in the adult mice
suggests that ZA may act differently depending on the age and bone
activity. Moreover, the fact that ZA is a known antiangiogenic
factor, but did not reduce vessel number or volume in bone raises
interesting questions regarding the mechanisms by which bone
angiogenesis occurs and how important their interdependency is
with bone modulation and activity. Further studies are necessary to
fully elucidate bone angiogenesis and its contribution to the bone
microenvironment. Collectively, the findings suggest that ZA
indirectly supports the osteoblastic niche and that the vasculature
Fig. 7. Gene expression analyses of bone marrow sorted cells: lineage negative (A,B), lineage positive (C), and unsorted total bone marrow cells (D). Bone marrow cells of
4-week-old mice treated with ZA for 4 weeks were sorted into Lin and Linþ cells by magnetic cell sorting beads (MACS) and gene expression analyzed by qPCR. (A) Lineage
negative cells had increased expression of BMP2, BMP6, BMi1, Tie2, Notch1, but no alteration of Ink4a, in mice treated with ZA versus vehicle (VEH) control. (B) Lineage
negative cells were also analyzed for calcium related genes. Cam1 and ClCa1 were decreased with ZA. (C) Lineage positive cells had decreased gene expression for BMP6 but no
significant changes were observed in Bmi1, Tie2, Notch1, Ink4a, and Flt3. (D) Total bone marrow cells had decrease gene expression of OCN and VCAM1 genes (P< 0.05,
p,0.005). Data are presented as mean SEM, n¼ 5/gp.
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niche may not be a key player in the augmented LSK population in
bone.
To account for an increase of LSK in the marrow, the present
study sought to determine whether ZA would affect other cell types
in the bone marrow. Analysis of hematopoietic CD41þcells revealed
similar levels between ZA and VEH. Moreover, investigation of
different LSK populations was performed to determine whether ZA
inhibited cell commitment that could account for the increased
population in the bone marrow. Indeed, short-term lymphocytic
reconstituting LSK Flt3þ cells were increased with ZA treatment.
Lymperi et al. [2011] demonstrated that inhibition of osteoclastic
resorption with alendronate treatment resulted in expansion of
hematopoietic progenitor cells (LSK) but with a decrease in the
absolute number of LSK Flt3HSCs and long-term culture-initiating
cells in the bone marrow. However, alendronate is a second
generation bisphosphonate with a lower efficacy of osteoclast
inhibition than ZA.
Gene expression of Lin sorted cells demonstrated that Bmi1
and Tie2, related with HSC self-renewal [Arai et al., 2004; Rizo
et al., 2008], were both increased, suggesting that hematopoietic
progenitor cells are acquiring self-renewal capacity. Interestingly,
BMP2 and BMP6 were both augmented with ZA treatment in Lin
negative cells. Jung et al. [2008] demonstrated that hematopoietic
stem cells participate in bone formation and niche activity with
secretion of BMP2 and BMP6. Later, a role of erythropoietin for
BMP2 and BMP6 production was reported [Shiozawa et al., 2010].
Indeed, the endosteal niche is expanded with ZA treatment and
hematopoietic progenitor cell could be actively participating in the
bone formation. It is possible that as osteoclasts are compromised
with ZA treatment their coupling factors to stimulate osteoblasts
(e.g., ephrins)are compromised and HPCs are serving to compensate.
Notch 1, a receptor for ligand Jagged 1 expressed by osteoblasts, was
also increased and is involved in the expansion of the HSC pool in
vivo [Calvi et al., 2003].
Altogether, accordingly with increased endosteal niches and
increased LSKs, our data suggest that ZA indirectly supports the
osteoblastic niche LSK expansion that occurs independent of the
vascular niche. Moreover, ZA has a differential response in the
vasculature modulation in young and adult mice, suggesting that
age and bone activity may be significant factors defining the
vasculature modulation in bone.
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